DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety of Intranasal Fentanyl (PecFent�) in the Treatment of Procedural Pain in the Elderly

Information source: University Hospital, Grenoble
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pain Due to Certain Specified Procedures

Intervention: intranasal fentanyl (Drug)

Phase: Phase 2/Phase 3

Status: Recruiting

Sponsored by: University Hospital, Grenoble

Overall contact:
Gavazzi Gaetan, MD, PHD, Phone: 0476765797, Ext: 33, Email: GGavazzi@chu-grenoble.fr

Summary

The purpose of this study is to evaluate the safety of the intranasal fentanyl in pain induced by wound care and rehabilitation in the elderly. The project would also provide a preliminary assessment of the effectiveness of intranasal fentanyl used in procedural pains.

Clinical Details

Official title: Safety of Intranasal Fentanyl (PecFent) in the Treatment of Procedural Pain in the Elderly With or Without Background Treatment.

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Safety of intranasal fentanyl as measured by the nature and frequency of adverse effects.

Secondary outcome:

Effectiveness of intranasal fentanyl in procedural pain using a VAS (Visual Analogic Scale) of pain.

Fentanyl impact on the goals of care as measured by a caregiver satisfaction scale.

Nurse or physiotherapist satisfaction regarding use of PecFent® as measured by a verbal descriptor scale

Impact of PecFent® on patient feelings during care or rehabilitation sessions as measured by a verbal descriptor scale

Detailed description: This is a safety clinical trial. This trial is monocentric, open label, non-randomized. Sixty elderly patients will be enrolled in this study, 30 with bedsore cares and 30 with rehabilitation sessions. Six bedsore cares or rehabilitation sessions will be assessed for each subject. For each session, patient pain will be evaluated using a visual analogic scale VAS at different times, before session, 5 minutes then 20 minutes after the beginning of the session, and a last VAS 1 hour after the end of the session. During the two first sessions, patients do not receive Pecfent® to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. An evaluation of respiratory rate and of the level of sedation will occur at different time : after 5 minutes then 20 minutes of care, at the end of the care session,at half an hour then one hour after the care session. At the end of sessions,

- The nurse or physiotherapist will assess their satisfaction regarding the objectives

achieved during the session with a four points verbal descriptor scale (very satisfied, satisfied, not much satisfied, not satisfied). They will also evaluate at the end of the four last session their satisfaction regarding the convenience of the use of pecfent® and its contribution towards care.

- Patients will assess their satisfaction regarding the course of the session with a

verbal descriptor scale (VDS) and their level of anxiety felt during the session with a VAS.

Eligibility

Minimum age: 76 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Hospitalized geriatric patient requiring care or rehabilitation

- Patient with pain during treatment or mobilization. (VAS ≥ 4)

- Written Informed consent

Exclusion Criteria:

- All unstable fractures

- Confusion: unable to assess their level of pain using a VAS.

- Contraindications to PecFent ® (. Hypersensitivity to the active substance or to any

of the excipients listed in section Composition Use in patients who had never received treatment for opioid severe respiratory depression or severe obstructive pulmonary disease.)

- Person under legal protection

Locations and Contacts

Gavazzi Gaetan, MD, PHD, Phone: 0476765797, Ext: 33, Email: GGavazzi@chu-grenoble.fr

University hospital of Grenoble, Grenoble, Isere 38043, France; Recruiting
Gavazzi Gaetan, MD, PHD, Phone: 0476765797, Ext: +33, Email: GGavazzi@chu-grenoble.fr
Additional Information

Starting date: November 2014
Last updated: May 27, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017